Results 101 to 105 of about 64,379 (105)

Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),

Blood, 2011
Elisabeth Wassner-Fritsch, Philippe Solal-Celigny, Corinne Haı̈Oun   +2 more
exaly  

Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263

Blood, 2010
Christian Klein, Sabine Bader, Frank Herting   +2 more
exaly  

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.

Blood, 2007
Christian Klein, Thomas Friess, Peter Sondermann   +2 more
exaly  

Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study

Blood, 2011
Andre H Goy, Giovanni Martinelli, Laurie H Sehn   +2 more
exaly  

Hydroxyurea Potentiates the Caspase-Independent Killing of B-Cell Lines by Rituximab and GA101

Oncology Research, 2013
exaly